Turnstone Biologics Corp. (TSBX)
Aug 11, 2025 - TSBX was delisted (reason: acquired by XOMA)
0.3550
0.00 (0.00%)
Inactive · Last trade price on Aug 8, 2025
Turnstone Biologics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
8.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 19.31M | -53.99M | -73.66% |
| Dec 31, 2022 | 73.30M | -27.99M | -27.64% |
| Dec 31, 2021 | 101.29M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTSBX News
- 6 months ago - Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights - GlobeNewsWire
- 7 months ago - Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 1 year ago - Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study - Benzinga
- 1 year ago - Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewsWire
- 1 year ago - Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer - GlobeNewsWire
- 1 year ago - Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewsWire
- 1 year ago - Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference - GlobeNewsWire